Drug reference
trimetazidine
Metabolic modulator; 3-ketoacyl coenzyme A thiolase inhibitor · Antianginal
Metabolic modulator; 3-ketoacyl coenzyme A thiolase inhibitorAntianginal
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Not yet extracted
Indications
Angina pectoris (add-on therapy)Ischaemic heart diseaseVisual disturbances (conclusive evidence lacking)Tinnitus (conclusive evidence lacking)Méniére’s disease (conclusive evidence lacking)Dizziness (conclusive evidence lacking)
Dosing
- Adult
- 20 mg TDS
Pharmacokinetics
Onset
absorbed orally
Half-life
6 hr
Metabolism
partly metabolized
Excretion
largely unchanged in urine
Side effects
Common
gastric burningdizzinessfatiguemuscle cramps
Serious
- reversible parkinsonism (in the elderly)
Drug interactions
5 additional unreviewed or low-confidence interactions hidden because their provenance or source detail is insufficient.
Related guidelines
Ask House about trimetazidine
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: KD Tripathi 7e, Goodman & Gilman 14e·Updated: 2026-05-10